Despite some setbacks, researchers developing antiangiogenesis treatments for cancer have persevered. Now the strategy is racking up new successes and earning credit even for conventional treatments.
No takes yet. Share an insight, caveat, or question.
Jean L. Marx (2003) studied this question.